Lexagene Holdings (Lexagene Holdings) Total Payout Ratio : 0.00 (As of May. 29, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Lexagene Holdings's current Total Payout Ratio is 0.00.

Lexagene Holdings Total Payout Ratio Historical Data

The historical data trend for Lexagene Holdings's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Total Payout Ratio Chart

Lexagene Holdings Annual Data

Trend

Mar13

Mar14

Mar15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Total Payout Ratio

Get a 7-Day Free Trial

1.27

0.47

0.86

0.93

0.47

Lexagene Holdings Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Total Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Lexagene Holdings's Total Payout Ratio

For the Medical Devices subindustry, Lexagene Holdings's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexagene Holdings's Total Payout Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lexagene Holdings's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Lexagene Holdings's Total Payout Ratio falls into.

Lexagene Holdings Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Lexagene Holdings's Total Payout Ratio for the fiscal year that ended in Feb. 2022 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	4.944	+	0)	/	-10.62
	=	0.47

Lexagene Holdings's Total Payout Ratio for the quarter that ended in Nov. 2022 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-1.678
	=	0.00

Lexagene Holdings Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexagene Holdings (Lexagene Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915

Website

https://www.lexagene.com

Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.